NO323230B1 - Mikrogranulater for kontrollert frigjoring for oral administrering som inneholder cisplatin, farmasoytiske preparater derav og anvendelse derav. - Google Patents
Mikrogranulater for kontrollert frigjoring for oral administrering som inneholder cisplatin, farmasoytiske preparater derav og anvendelse derav. Download PDFInfo
- Publication number
- NO323230B1 NO323230B1 NO19993881A NO993881A NO323230B1 NO 323230 B1 NO323230 B1 NO 323230B1 NO 19993881 A NO19993881 A NO 19993881A NO 993881 A NO993881 A NO 993881A NO 323230 B1 NO323230 B1 NO 323230B1
- Authority
- NO
- Norway
- Prior art keywords
- microgranules
- cisplatin
- stated
- coating
- mixture
- Prior art date
Links
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 title claims abstract description 89
- 229960004316 cisplatin Drugs 0.000 title claims abstract description 88
- 238000013270 controlled release Methods 0.000 title claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 7
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 6
- 238000011319 anticancer therapy Methods 0.000 claims abstract description 3
- 239000013066 combination product Substances 0.000 claims abstract description 3
- 229940127555 combination product Drugs 0.000 claims abstract description 3
- 239000011248 coating agent Substances 0.000 claims description 34
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 22
- 238000000576 coating method Methods 0.000 claims description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 108010006654 Bleomycin Proteins 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 229960001561 bleomycin Drugs 0.000 claims description 6
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000010410 layer Substances 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 239000000454 talc Substances 0.000 claims description 5
- 229910052623 talc Inorganic materials 0.000 claims description 5
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical group FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
- 229960002949 fluorouracil Drugs 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 239000004014 plasticizer Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 239000001069 triethyl citrate Substances 0.000 claims description 3
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 3
- 235000013769 triethyl citrate Nutrition 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 3
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 claims description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 2
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N Gimeracil Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000012736 aqueous medium Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 229950009822 gimeracil Drugs 0.000 claims description 2
- 229950000193 oteracil Drugs 0.000 claims description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 239000011253 protective coating Substances 0.000 claims description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims description 2
- 229960001674 tegafur Drugs 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 12
- 238000009472 formulation Methods 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 abstract description 5
- 238000009096 combination chemotherapy Methods 0.000 abstract description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 16
- 241000282472 Canis lupus familiaris Species 0.000 description 10
- 229910052697 platinum Inorganic materials 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000003111 delayed effect Effects 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 206010029155 Nephropathy toxic Diseases 0.000 description 5
- 231100000417 nephrotoxicity Toxicity 0.000 description 5
- 230000007694 nephrotoxicity Effects 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000007972 injectable composition Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000004531 microgranule Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229920003153 Eudragit® NE polymer Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000013435 necrotic lesion Diseases 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9701545A FR2759293B1 (fr) | 1997-02-11 | 1997-02-11 | Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie |
| PCT/FR1998/000251 WO1998034599A1 (fr) | 1997-02-11 | 1998-02-10 | Microgranules contenant du cisplatine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO993881D0 NO993881D0 (no) | 1999-08-11 |
| NO993881L NO993881L (no) | 1999-09-29 |
| NO323230B1 true NO323230B1 (no) | 2007-02-05 |
Family
ID=9503556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19993881A NO323230B1 (no) | 1997-02-11 | 1999-08-11 | Mikrogranulater for kontrollert frigjoring for oral administrering som inneholder cisplatin, farmasoytiske preparater derav og anvendelse derav. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US6458389B1 (enExample) |
| EP (1) | EP0971702B1 (enExample) |
| JP (1) | JP4549445B2 (enExample) |
| KR (1) | KR100471672B1 (enExample) |
| AR (1) | AR011133A1 (enExample) |
| AT (1) | ATE255409T1 (enExample) |
| BG (1) | BG64247B1 (enExample) |
| BR (1) | BR9807319A (enExample) |
| CA (1) | CA2282082C (enExample) |
| DE (1) | DE69820239T2 (enExample) |
| DK (1) | DK0971702T3 (enExample) |
| EA (1) | EA001760B1 (enExample) |
| ES (1) | ES2210726T3 (enExample) |
| FR (1) | FR2759293B1 (enExample) |
| HU (1) | HU225425B1 (enExample) |
| IL (1) | IL131326A (enExample) |
| IN (1) | IN187998B (enExample) |
| NO (1) | NO323230B1 (enExample) |
| NZ (1) | NZ337216A (enExample) |
| PL (1) | PL191631B1 (enExample) |
| PT (1) | PT971702E (enExample) |
| TW (1) | TW561055B (enExample) |
| WO (1) | WO1998034599A1 (enExample) |
| ZA (1) | ZA981123B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050096304A1 (en) * | 1998-09-08 | 2005-05-05 | David White | Method of treating cancer using dithiocarbamate derivatives |
| FR2790668B1 (fr) * | 1999-03-12 | 2002-07-26 | D B F | Granules contenant une substance vegetale et leur procede de preparation |
| JP2002544220A (ja) * | 1999-05-17 | 2002-12-24 | デー．ベー．エフ． | 植物物質を含有する顆粒及びその製造方法 |
| JP5171038B2 (ja) * | 2003-10-10 | 2013-03-27 | エティファルム | イチョウ・エキスを含む放出持続性の微小顆粒およびそのような顆粒の製造方法 |
| FR2861990B1 (fr) * | 2003-11-10 | 2006-02-10 | Nouveaux Produits Pharma | Comprimes faiblement doses a reseau de polymeres |
| TW200631609A (en) * | 2004-11-18 | 2006-09-16 | Bristol Myers Squibb Co | Enteric coated bead comprising ixabepilone, and preparation and administration thereof |
| US20080069901A1 (en) * | 2004-12-10 | 2008-03-20 | Tmrc Co. , Ltd. | Therapeutic Agent for Metastatic Cancer and Cancer Metastasis Inhibitor |
| US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
| FR2918566B1 (fr) | 2007-07-11 | 2009-10-09 | Pierre Fabre Medicament Sa | Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine. |
| FR2918567B1 (fr) * | 2007-07-11 | 2012-08-03 | Pf Medicament | Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine. |
| MX2010003032A (es) * | 2007-09-21 | 2010-04-09 | Evonik R Hm Gmbh | Composicion farmaceutica opioide de liberacion controlada ph dependiente con resistencia contra la influencia del etanol. |
| CN101801356B (zh) * | 2007-09-21 | 2016-10-19 | 赢创罗姆有限公司 | 耐受乙醇影响的非阿片类的pH依赖性受控释放的药物组合物 |
| CA2711475A1 (en) * | 2008-01-10 | 2009-07-16 | Evonik Roehm Gmbh | Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release |
| ES2626078T3 (es) * | 2008-01-10 | 2017-07-21 | Evonik Röhm Gmbh | Preparación farmacéutica o nutracéutica revestida con liberación de sustancia activa mejorada en el colon |
| DK177529B1 (en) * | 2009-10-23 | 2013-09-08 | Bio Bedst Aps | Liposomes with improved storage stability |
| CA2688202C (en) * | 2009-12-11 | 2012-11-13 | Bj Services Company | Viscoelastic fluids containing hydroxyethyl cellulose |
| EP2371356B1 (en) * | 2010-03-12 | 2012-12-19 | Phoeme GmbH | Multi-particle pharmaceutical formulation for colon absorption |
| US8070047B1 (en) * | 2010-12-02 | 2011-12-06 | Rohm And Haas Electronic Materials Llc | Flux composition and method of soldering |
| CA2883703C (en) | 2012-09-04 | 2021-10-19 | Eleison Pharmaceuticals, Llc | Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin |
| CA2959414C (en) | 2014-09-05 | 2023-03-14 | Symbiomix Therapeutics, Llc | Secnidazole for use in the treatment of bacterial vaginosis |
| WO2016169042A1 (en) * | 2015-04-24 | 2016-10-27 | Genedia Biotech Co. Ltd. | Combination therapies for bladder cancer |
| WO2016196653A1 (en) * | 2015-06-01 | 2016-12-08 | Symbiomix Therapeutics, Llc | Novel nitroimidazole formulations and uses thereof |
| JP6912394B2 (ja) | 2015-06-12 | 2021-08-04 | バクサート インコーポレイテッド | Ｒｓｖおよびノロウイルス抗原の小腸送達のための製剤 |
| TWI795462B (zh) | 2017-11-17 | 2023-03-11 | 日商鹽野義製藥股份有限公司 | 光安定性及溶出性優異的醫藥製劑 |
| EP3785716A4 (en) | 2018-04-24 | 2022-03-02 | Shionogi & Co., Ltd | SOLID FORMULATION WITH EXCELLENT STABILITY |
| WO2019208540A1 (ja) | 2018-04-24 | 2019-10-31 | 塩野義製薬株式会社 | 安定性に優れた固形製剤 |
| US12280037B2 (en) | 2020-09-22 | 2025-04-22 | Evofem Biosciences, Inc. | Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3172570D1 (en) * | 1981-03-11 | 1985-11-14 | Mirko Beljanski | Serpentine, alstonine and sempervirine drugs for the specific inhibition of tumurous and cancerous cells |
| IT1153974B (it) * | 1982-09-23 | 1987-01-21 | Erba Farmitalia | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
| DE3421468A1 (de) * | 1984-06-08 | 1985-12-19 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung |
| DE3523454A1 (de) * | 1985-07-01 | 1987-01-08 | Eberhard Prof Dr Nuernberg | Formkoerper |
| US4925674A (en) * | 1988-08-25 | 1990-05-15 | Himedics, Inc. | Amoxicillin microencapsulated granules |
| US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| JPH05294839A (ja) * | 1992-04-20 | 1993-11-09 | Biomaterial Universe Kk | シスプラチン含有生体内分解吸収性高分子の微小球お よびその製造法 |
| US5795882A (en) * | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
| JPH07112932A (ja) * | 1993-08-27 | 1995-05-02 | Mitsui Toatsu Chem Inc | 徐放性医薬製剤 |
| JPH0789849A (ja) * | 1993-09-20 | 1995-04-04 | Fujisawa Pharmaceut Co Ltd | 徐放性製剤 |
| JPH0859460A (ja) * | 1994-08-22 | 1996-03-05 | Tanaka Kikinzoku Kogyo Kk | 抗ガン剤内包キトサンミクロスフェア及びその製造法 |
| US5637319A (en) * | 1995-03-01 | 1997-06-10 | Takada; Kanji | Controlled-release preparations |
| US5614206A (en) * | 1995-03-07 | 1997-03-25 | Wright Medical Technology, Inc. | Controlled dissolution pellet containing calcium sulfate |
| PT929293E (pt) * | 1996-08-23 | 2004-03-31 | Sequus Pharm Inc | Lipossomas contendo um composto de cisplatina |
-
1997
- 1997-02-11 FR FR9701545A patent/FR2759293B1/fr not_active Expired - Lifetime
-
1998
- 1998-02-10 TW TW087101722A patent/TW561055B/zh not_active IP Right Cessation
- 1998-02-10 CA CA002282082A patent/CA2282082C/fr not_active Expired - Lifetime
- 1998-02-10 JP JP53389798A patent/JP4549445B2/ja not_active Expired - Lifetime
- 1998-02-10 BR BR9807319-2A patent/BR9807319A/pt not_active Application Discontinuation
- 1998-02-10 AT AT98908157T patent/ATE255409T1/de active
- 1998-02-10 IN IN337DE1998 patent/IN187998B/en unknown
- 1998-02-10 PT PT98908157T patent/PT971702E/pt unknown
- 1998-02-10 IL IL13132698A patent/IL131326A/xx not_active IP Right Cessation
- 1998-02-10 WO PCT/FR1998/000251 patent/WO1998034599A1/fr not_active Ceased
- 1998-02-10 EP EP98908157A patent/EP0971702B1/fr not_active Expired - Lifetime
- 1998-02-10 HU HU0001719A patent/HU225425B1/hu not_active IP Right Cessation
- 1998-02-10 US US09/367,270 patent/US6458389B1/en not_active Expired - Lifetime
- 1998-02-10 PL PL335107A patent/PL191631B1/pl not_active IP Right Cessation
- 1998-02-10 EA EA199900734A patent/EA001760B1/ru not_active IP Right Cessation
- 1998-02-10 ES ES98908157T patent/ES2210726T3/es not_active Expired - Lifetime
- 1998-02-10 KR KR10-1999-7007263A patent/KR100471672B1/ko not_active Expired - Fee Related
- 1998-02-10 DK DK98908157T patent/DK0971702T3/da active
- 1998-02-10 NZ NZ337216A patent/NZ337216A/xx not_active IP Right Cessation
- 1998-02-10 DE DE69820239T patent/DE69820239T2/de not_active Expired - Lifetime
- 1998-02-11 AR ARP980100613A patent/AR011133A1/es active IP Right Grant
- 1998-02-11 ZA ZA981123A patent/ZA981123B/xx unknown
-
1999
- 1999-08-10 BG BG103647A patent/BG64247B1/bg unknown
- 1999-08-11 NO NO19993881A patent/NO323230B1/no not_active IP Right Cessation
-
2002
- 2002-07-25 US US10/200,998 patent/US20030017210A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO323230B1 (no) | Mikrogranulater for kontrollert frigjoring for oral administrering som inneholder cisplatin, farmasoytiske preparater derav og anvendelse derav. | |
| US20230141842A1 (en) | Compounds to Modulate Intestinal Absorption of Nutrients | |
| KR101660927B1 (ko) | 약염기성 약물 및 유기산을 포함하는 약물 전달 시스템 | |
| EP2493456B1 (en) | Solid dispersion of rifaximin | |
| KR102512475B1 (ko) | 칼슘 락테이트 조성물 및 사용 방법 | |
| CN1316901A (zh) | 富马酸衍生物在移植药物中的应用 | |
| CN102036656A (zh) | 含有蜡的缓释制剂 | |
| CS268819B2 (en) | Method of particles production with effective substance's controlled loosening | |
| JPH07501343A (ja) | 経口用１α−ヒドロキシプレビタミンＤ | |
| HUE032368T2 (en) | Antisense compositions and methods of making and using same | |
| EP3236963B1 (en) | Method of treatment | |
| EP2812074B1 (en) | Modified release formulations of viloxazine | |
| WO2000050015A1 (en) | Pharmaceutical capsule compositions containing loratadine and pseudoephedrine | |
| KR101018894B1 (ko) | 체내 흡수가 증진된 탈니플루메이트 함유 서방정 | |
| EP3429565B1 (en) | Prolonged release pharmaceutical composition comprising cysteamine or salt thereof | |
| KR20110091252A (ko) | 미코페놀레이트 모페틸을 함유한 서방성 면역 억제제 | |
| MXPA99007393A (en) | Microgranules containing cisplatin | |
| CN101234096A (zh) | 匹多莫德胶囊制剂及其制备方法 | |
| CN1442132A (zh) | 含有2－[(4－甲氧基－3－甲基)－2－吡啶基]甲基亚磺酰基－5－(1h－吡咯－1－基)－1h－苯并咪唑的肠溶包衣微粒制剂 | |
| HK1175114B (en) | Solid dispersion of rifaximin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |